Interfaces
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


INTERFACES
Vol. 28, No. 3, May-June 1998, pp. 144-166
DOI: 10.1287/inte.28.3.144
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Edwards, D. M.
Right arrow Articles by Owens, D. K.
Right arrow Search for Related Content

A Dynamic HIV-Transmission Model for Evaluating the Costs and Benefits of Vaccine Programs

Donna M. Edwards, Ross D. Shachter, Douglas K. Owens

Systems Research Department (MS-9201), Sandia National Laboratories, PO Box 969, Livermore, California 94551-0969
Department of Engineering-Economic Systems and Operations Research, Stanford University, Stanford, California 94305
VA Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, California 94304 and Department of Medicine, Stanford University, Stanford, California 94305

We developed a dynamic model of HIV transmission to evaluate the costs and benefits of HIV-vaccine programs in a population of homosexual men. We examined how changes in high-risk sexual behavior and the growth pattern of the epidemic influence the cost-effectiveness of preventive vaccines and of therapeutic vaccines. We found that the effect of reductions in condom use is more important for therapeutic vaccines than for preventive vaccines. Therapeutic vaccines may increase HIV seroprevalence in the population, unless the vaccine program is accompanied by increased condom use. Epidemic growth patterns also influence the cost-effectiveness of both vaccines, but the effects are more pronounced for preventive vaccines, which are more cost-effective in an early-stage epidemic than in a late-stage epidemic.

Key Words: health care; epidemiology; dynamic programming; models



This article has been cited by other articles:


Home page
Med Decis MakingHome page
C. T. Bauch, A. M. Anonychuk, T. Van Effelterre, B. Z. Pham, and M. F. Merid
Incorporating Herd Immunity Effects into Cohort Models of Vaccine Cost-Effectiveness
Med Decis Making, September 1, 2009; 29(5): 557 - 569.
[Abstract] [PDF]


Home page
Management ScienceHome page
G. S. Zaric, M. L. Brandeau, and P. G. Barnett
Methadone Maintenance and HIV Prevention: A Cost-Effectiveness Analysis
Management Science, August 1, 2000; 46(8): 1013 - 1031.
[Abstract] [PDF]


Home page
InterfacesHome page
J. G. Kahn, M. L. Brandeau, and J. Dunn-Mortimer
OR Modeling and AIDS Policy: From Theory to Practice
Interfaces, May 1, 1998; 28(3): 3 - 22.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by INFORMS.